Low frequency of elevated prothrombin times in patients with lupus anticoagulants when using a recombinant thromboplastin reagent: Implications for dosing and monitoring of oral anticoagulant therapy

British Journal of Biomedical Science

Volumn 62, Issue 1, 2005, Pages 15-18

  Moore, Gary W ^a   Rangarajan, S ^a   Holland, L J ^a   Henley, A ^a   Savidge, G F ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Lupus anticoagulant; Oral anticoagulant therapy; Prothrombin time; Recombinant thromboplastin

Indexed keywords

ANTICOAGULANT AGENT; LUPUS ANTICOAGULANT; PROTHROMBIN; REAGENT; RECOMBINANT THROMBOPLASTIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; DOSE CALCULATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; PATIENT MONITORING; PREVALENCE; PRIORITY JOURNAL; PROTHROMBIN TIME; RETROSPECTIVE STUDY; THROMBOPHILIA; THROMBOSIS;

EID: 16444378464     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2005.11732681     Document Type: Article

References (26)

1. Arnout J. Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants. Thromb Haemost 2001; 86: 83-91.
2. Sanfelippo MJ, Sennet J, McMahon EJ. Falsely elevated INRs in warfarin-treated patients with the lupus anticoagulant. WMJ 2000; 99: 62-4.
3. Delia Valle P, Crippa L, Garlando AM et al. Interference of lupus anticoagulants in prothrombin time assays: implications for selection of adequate methods to optimise the management of thrombosis in the antiphospholipid syndrome. Haematologica 1999; 84: 1065-74.
4. Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997; 127: 177-85.
5. Robert A, Le Querrec A, Delahousse B et al. Control of oral anticoagulation in patients with the antiphospholipid syndrome - influence of the lupus anticoagulant on international normalised ratio. Thromb Haemost 1998; 80: 99-103.
6. Tripodi A, Chantarangkul V, Clerici M, Negri B, Galli M, Mannucci PM. Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins. Br J Haematol 2001; 115: 672-8.
7. Arnout J, Vanrusselt M, Huybrechts E, Vermylen J. Optimisation of the dilute prothrombin time for the detection of lupus anticoagulant by use of a recombinant tissue thromboplastin. Br J Haematol 1994; 87: 94-9.
8. Machin SJ, Giddings JC, Greaves M et al. Guidelines on testing for the lupus anticoagulant. J Clin Pathol 1991; 44: 885-9.
9. Moore GW, Smith MP, Patel Y, Savidge GF. The Activated Seven Lupus Anticoagulant (ASLA) assay: a new test for lupus anticoagulants (LAs). Evidence that some LAs are detectable only in extrinsic pathway based assays. Blood Coagul Fibrinolysis 2002; 13: 261-9.
10. Greaves M, Cohen H, Machin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000; 109: 704-15.
11. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995; 74(4): 1185-90.
12. Gardiner C, Mackie IJ, Malia RG et al. The importance of locally derived reference ranges and standardised calculation of dilute Russell's viper venom time results in screening for lupus anticoagulant. Br J Haematol 2000; 111: 1230-5.
13. Della Valle P, Crippa L, Safa O et al. Potential failure of the international normalised ratio (INR) in the monitoring of oral anticoagulation in patients with lupus anticoagulants. Ann Méd Interne 1996; 147 (Suppl 1): 10-4.
14. Lawrie AS, Purdy G, Mackie IJ, Machin SJ. Monitoring of oral anticoagulant therapy in lupus anticoagulant positive patients with the anti-phospholipid syndrome. Br J Haematol 1997; 98: 887-92.
15. Bijsterveld NR, Middledorp S, Berends F, Buller HR. Monitoring therapy with vitamin K antagonists in patients with lupus anticoagulant: effect on different tests for INR determination. JThromb Thrombolysis 2000; 9: 263-9.
16. Arnout J, Vermylen J. Lupus anticoagulant: influence on the international normalised ratio. Thromb Haemost 1999; 81: 847-9.
17. Crowther MA, McDonald E, Johnston M, Cook D. Vitamin K deficiency and D-dimer levels in the intensive care unit: a prospective cohort study. Blood Coagul Fibrinolysis 2002; 13: 49-52.
18. Fujita S, Kagawa K, Fukutake K. Introduction of international normalised ratio of prothrombin time to evaluate multiple depletions of coagulation factors. Rinsho Byori 2002; 50: 618-24.
19. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
20. Dzik WH. Predicting haemorrhage using preoperative coagulation screening assays. Curr Hematol Rep 2004; 3: 324-30.
21. Rapaport SI, Le DT. Thrombosis in the antiphospholipid syndrome (Letter). N Engl J Med 1995; 333: 665.
22. Ginsberg JS, Wells PS, Brill-Edwards P et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-91.
23. Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 303-8.
24. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332; 993-7.
25. Crowther MA, Ginsberg JS, Julian J et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-8.
26. UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation. Report on Survey 141. (2004) www.ukneqasbc.org.